DOCN
DigitalOcean Holdings, Inc.
DOCN trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over DOCN overall, supported by stronger valuation and stronger modeled upside.
DOCN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Strong | |
| Strong |
DOCN's revenue, cash flow and balance sheet are currently strong, and its profitability is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DOCN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $7.61 | -92% |
| Fair | 46x | $13.68 | -85% |
| Forward | 55x | $90.07 | — |
| Expensive | 68x | $20.36 | -77% |
| Current | 300x | $90.07 | — |
Historical ranges are pointers, not guarantees.
DOCN's PE is in its expensive range at 300x. If earnings grow as analysts expect, today's price would be 55x next year's earnings, in its fair range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DOCN in the historical PE scenario, which offers more potential upside but is not a forecast.
DOCN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for DOCN, but weaker profitability. However, they disagree widely on these estimates.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
DOCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.64 | +448% |
| Q3 2026 | $0.30 | -88% |
| Q2 2026 | $2.18 | +68% |
| Q1 2026 | $2.28 | +105% |
| Q4 2025 | $2.52 | +190% |
| Q3 2025 | $2.48 | +195% |
| Q2 2025 | $1.30 | +83% |
| Q1 2025 | $1.11 | +113% |
| Q4 2024 | $0.87 | +335% |
DOCN earned $0.30 per share over the past year, down 88% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA's earnings per share have climbed steadily: $7.91 over the past year, up 125% from the year before, and higher year over year for 13 quarters in a row.
DOCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $321.2M | +40% |
| Q2 2026 | $281.2M | +29% |
| Q1 2026 | $257.9M | +22% |
| Q4 2025 | $242.4M | +18% |
| Q3 2025 | $229.6M | +16% |
| Q2 2025 | $218.7M | +14% |
| Q1 2025 | $210.7M | +14% |
| Q4 2024 | $204.9M | +13% |
DOCN's revenue has grown year over year every quarter since early 2021: $321M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -9.3 points |
| Q2 2026 | 10% | -5.8 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 16% | +0.1 points |
| Q3 2025 | 20% | +7.2 points |
| Q2 2025 | 16% | +4.7 points |
| Q1 2025 | 18% | +12 points |
| Q4 2024 | 16% | +9.8 points |
DOCN's operating margin was 10% last quarter, down 9.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DOCN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DOCN on profitability, with a higher operating margin.
DOCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $137.7M | +56% |
| Q2 2026 | $68.4M | +15% |
| Q1 2026 | $6.9M | +226% |
| Q4 2025 | $31.1M | +19% |
| Q3 2025 | $88M | +450% |
| Q2 2025 | $59.3M | +50% |
| Q1 2025 | $2.1M | -91% |
| Q4 2024 | $26.1M | -7.9% |
DOCN generated $244M in free cash flow over the past year, up 39% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DOCN on cash flow, with more consistent year-over-year improvement.
DOCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.4% | -11.9M shares |
| 1 year | +8.7% | +9.2M shares |
| 3 years | +12% | +12M shares |
| 5 years | +6.2% | +6.7M shares |
| Available history | +32% | +27.6M shares |
DOCN has 115M diluted shares, up 8.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $2.9M |
| Q2 2025 | $20.1M |
| Q1 2025 | $59.1M |
| Q4 2024 | $29.9M |
DOCN hasn't bought back shares in the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over DOCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DOCN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 4.3x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.8x | High |
DOCN has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
DOCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 11.0 | Oversold |
DOCN's weekly RSI is 42 (neutral) and its Stochastic is 11 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DOCN PE vs Technology Sector
| Metric | DOCN | Sector median | Relative |
|---|---|---|---|
| PE | 300x | 28x | 978% above |
| PE % | 100 | 41 | 59 pts above |
DOCN is trading at 300x earnings, a 978% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over DOCN on valuation relative to its sector.
DOCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $107.3 | 16% below |
| 20 week MA | $116.3 | 23% below |
| 50 week MA | $101.1 | 11% below |
| 100 week MA | $68.0 | 33% above |
| 200 week MA | $51.5 | 75% above |
DOCN has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
DOCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $41.6 | $81.3 | +95% |
| 2022 | $81.3 | $24.8 | -70% |
| 2023 | $24.8 | $36.7 | +48% |
| 2024 | $36.7 | $34.9 | -4.8% |
| 2025 | $34.9 | $49.5 | +42% |
| 2026 YTD | $49.5 | $90.1 | +82% |
DOCN has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.